An engineered substance P variant for receptor-mediated delivery of synthetic antibodies into tumor cells
- 7 July 2009
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 106 (27) , 11011-11015
- https://doi.org/10.1073/pnas.0904907106
Abstract
We have developed and tested a robust delivery method for the transport of proteins to the cytoplasm of mammalian cells without compromising the integrity of the cell membrane. This receptor-mediated delivery (RMD) technology utilizes a variant of substance P (SP), a neuropeptide that is rapidly internalized upon interaction with the neurokinin-1 receptor (NK1R). Cargos in the form of synthetic antibody fragments (sABs) were conjugated to the engineered SP variant (SPv) and efficiently internalized by NK1R-expressing cells. The sABs used here were generated to bind specific conformational forms of actin. The internalized proteins appear to escape the endosome and retain their binding activity within the cells as demonstrated by co-localization with the actin cytoskeleton. Further, since the NK1R is over-expressed in many cancers, SPv-mediated delivery provides a highly specific method for therapeutic utilization of affinity reagents targeting intracellular processes in diseased tissue.Keywords
This publication has 28 references indexed in Scilit:
- High-throughput Generation of Synthetic Antibodies from Highly Functional Minimalist Phage-displayed LibrariesJournal of Molecular Biology, 2007
- Phage display for engineering and analyzing protein interaction interfacesCurrent Opinion in Structural Biology, 2007
- shRNA and siRNA delivery to the brainAdvanced Drug Delivery Reviews, 2007
- Real-Time Reverse Transcription-PCR Quantitation of Substance P Receptor (NK-1R) mRNAClinical and Vaccine Immunology, 2005
- Advanced transfection with Lipofectamine 2000 reagent: primary neurons, siRNA, and high-throughput applicationsMethods, 2004
- Tachykinins in the control of breathing by hypoxia: pre- and post-genomic eraRespiratory Physiology & Neurobiology, 2003
- In Vitro Assays of Processive Myosin MotorsMethods, 2000
- The role of tachykinins via NK1 receptors in progression of human gliomasLife Sciences, 2000
- A novel receptor-targeted gene delivery system for cancer gene therapyScience China Life Sciences, 1999
- Inhibition of Hyperalgesia by Ablation of Lamina I Spinal Neurons Expressing the Substance P ReceptorScience, 1997